Pretreatment of roxadustat (10 mg/kg/day in vivo and 10 μM in vitro) protects against ischemia-induced acute kidney injury (AKI) via improving CD73 and decreasing AIM2 inflammasome activation (Yang et al., 2023). This evidence concerns the gene NT5E and acute kidney injury.